Iovance Biotherapeutics, Inc. IOVA Business Segments — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s business segments — research and development expense?
- Iovance Biotherapeutics, Inc. (IOVA) reported business segments — research and development expense of $57.37M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s business segments — research and development expense changed year-over-year?
- Iovance Biotherapeutics, Inc.'s business segments — research and development expense decreased by 13.1% year-over-year, from $66.05M to $57.37M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s business segments — research and development expense?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s business segments — research and development expense has grown at a -4.3% compound annual growth rate (CAGR), from $298.27M to $273.06M.
- What does business segments — research and development expense mean?
- This tracks the investment in clinical trials, laboratory research, and regulatory activities required to develop and advance the company's pipeline. For a biopharmaceutical firm, this is the primary driver of future growth and long-term value creation.